Results from a phase II, open-label, randomized study (SIGN) comparing gefitinib with docetaxel as second-line therapy in patients with advanced (stage IIIb or IV) non-small-cell lung cancer

2005 ◽  
Vol 23 (16_suppl) ◽  
pp. 7035-7035 ◽  
Author(s):  
T. Cufer ◽  
E. Vrdoljak
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Randomized Study ◽  
Small Cell ◽  
Advanced Stage ◽  
Second Line ◽  
Small Cell Lung ◽  
Open Label ◽  
Second Line Therapy ◽  
Line Therapy

Second-line therapy with gefitinib in combination with docetaxel for advanced non-small cell lung cancer: a phase II randomized study

2007 ◽  
Vol 2 (2) ◽  
pp. 63-71
Author(s):  
G. Robinet ◽  
F. Barlesi ◽  
P. Fournel ◽  
H. Berard ◽  
R. Corre ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Phase Ii ◽  
Cell Lung Cancer ◽  
Randomized Study ◽  
Small Cell ◽  
Second Line ◽  
Small Cell Lung ◽  
Second Line Therapy ◽  
Line Therapy

scholarly journals Phase II, Double-Blinded, Randomized Study of Enzastaurin Plus Pemetrexed as Second-Line Therapy in Patients with Advanced Non-small Cell Lung Cancer

2010 ◽  
Vol 5 (3) ◽  
pp. 369-375 ◽  
Author(s):  
Alberto Chiappori ◽  
Gerold Bepler ◽  
Fabrice Barlesi ◽  
Jean-Charles Soria ◽  
Martin Reck ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Phase Ii ◽  
Randomized Study ◽  
Small Cell ◽  
Second Line ◽  
Small Cell Lung ◽  
Second Line Therapy ◽  
Line Therapy ◽  
Double Blinded
Sign in / Sign up

Export Citation Format

Share Document